Download Targeting multiple genetic aberrations in isolated tumor cells by

DP
RO
Targeting multiple genetic aberrations in isolated tumor cells by
spectral fluorescence in situ hybridization
3
4
Marilyn L. Slovak, PhD a,c,∗ , Feiyu Zhang, MS a , Lucene Tcheurekdjian, BS a ,
Dolores Bobadilla, BS a , Victoria Bedell, BS a , Daniel A. Arber, MD b , Diane L. Persons, MD c ,
Jeffrey A. Sosman, MD d , Joyce L. Murata-Collins, PhD a
5
6
7
8
9
10
11
12
13
OF
Cancer Detection and Prevention 32 (2002) 1–9
a
Department of Cytogenetics, City of Hope National Medical Center, Room 2255, Northwest Building, 1500 East Duarte Road, Duarte, CA 91010-3000, USA
b Department of Anatomic Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA
c Department of SWOG Cytogenetics Committees, Southwest Oncology Group (SWOG-9431), Operations Office,
14980 Omicron Drive, San Antonio, TX 78245-3217, USA
d Department of Melanoma Committees, Southwest Oncology Group (SWOG-9431), Operations Office,
14980 Omicron Drive, San Antonio, TX 78245-3217, USA
Received 27 April 2002; received in revised form 2 May 2002; accepted 2 May 2002
14
TE
15
Abstract
17
26
Purpose: Tumorigenesis is characterized by the stepwise accumulation of multiple genetic changes that modify specific growth controls
and cell survival. Conventional fluorescence in situ hybridization (FISH) assays reliably target one to three probes in a single hybridization.
Simultaneous detection of more than three chromosomal or gene targets should increase the overall power of molecular cytogenetics by
permitting detection of multiple genetic aberrations at the single cell level. Method: Spectral FISH is an innovative molecular cytogenetic
approach that can target many specific chromosomal aberrations in interphase and metaphase cells in a single hybridization, using combinatorial fluorescence and digital imaging microscopy. Results: S-FISH is a reliable means to identify disease-specific aberrations at the
DNA level in individual tumor cells in hematopoietic disorders and malignant melanoma. Conclusion: S-FISH is a sensitive assay for the
diagnosis and monitoring of disease-specific or patient-specific genetic aberrations, with significant clinical application in oncology for
early detection of new or re-emerging abnormal clones, allowing for earlier therapeutic intervention. © 2002 Published by Elsevier Science
Ltd. on behalf of International Society for Preventive Oncology.
27
Keywords: FISH; Spectral FISH; Molecular cytogenetics; DNA; Minimal residual disease; Spectral imaging
19
20
21
22
23
24
25
28
RR
18
EC
16
1. Introduction
30
Human cancers have been defined as clonal disorders
arising from single cells that have accumulated multiple
mutations either through inherited germline alterations or
by acquired mutations of somatic cellular genes by environmental factors. Biologic and epidemiological evidence
suggest that tumor formation is a consequence of multiple genetic hits resulting in dysregulation of genes affecting immortalization, transformation, cell cycle progression
and checkpoint pathways, invasion/metastasis and angiogenesis. In both hematopoietic disorders and solid tumors,
these genetic alterations are manifest as non-random chromosomal aberrations. Many of these aberrations are diag-
32
33
34
35
36
37
38
39
40
41
∗
UN
31
CO
29
Corresponding author. Tel.: +1-626-359-8111x62313;
fax: +1-626-301-8877.
E-mail address: [email protected] (M.L. Slovak).
1
2
nostic and prognostic markers, e.g. chromosome region 9p21
has been observed in chromosomal inversions, translocations, heterozygous deletions and homozygous deletions in
malignant cells from glioma, non-small cell lung cancer,
leukemia and melanoma. This locus indicates the involvement of cyclin-dependent kinase inhibitor-2A (CDKN2A,
also referred to as p16 or p16I NK4a ) genes in the genesis of
several tumor types [1,2]. The rapid and reliable detection of
critical genetic lesions in patient specimens can contribute to
improved cancer risk assessment, prognostication of tumor
behavior, and detection of minimal residual disease. Furthermore, the development of cancer drugs that target specific genetic abnormalities, such as HER2/neu gene amplification and Herceptin® therapy in breast cancer or t(9;22)
translocations and Gleevac® therapy in chronic myeloid
leukemia emphasizes the clinical value of defining appropriate molecular targets that direct novel therapeutic strategies
[3].
0361-090X/02/$ – see front matter © 2002 Published by Elsevier Science Ltd. on behalf of International Society for Preventive Oncology.
PII: S 0 3 6 1 - 0 9 0 X ( 0 2 ) 0 0 0 6 3 - 6
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
DNA-based molecular evaluation of chromosomal regions
is known as fluorescence in situ hybridization (FISH). FISH
assays permit reliable detection of one to three targets in a
single hybridization. However, ploidy heterogeneity within
a tumor could mask a specific gain or loss of a genetic locus unless a second (identifier) or several probes were used
simultaneously. Simultaneous detection of multiple chromosomal or gene targets would relieve this concern and increase
the overall information generated from FISH assays at the
single cell level.
Previously, we described the use of an innovative molecular cytogenetic approach termed spectral FISH or S-FISH
that targeted multiple numeric chromosomal aberrations
or aneuploidy in interphase nuclei in a single hybridization, using combinatorial fluorescence and digital imaging
microscopy [4]. We now demonstrate the application of
S-FISH using locus-specific FISH probe panels to survey
for the presence or absence of recurring disease-specific
aberrations in the hematopoietic disorders and malignant
melanoma. The panels were selected to target locus-specific
sites associated with tumor progression (i.e. molecular
markers of metastatic melanoma) and the commonly observed non-random cytogenetic aberrations observed in
therapy-related myelodysplasia/acute leukemia. The potential clinical utility of the latter to screen autologous stem
cell aliquots prior to transplantation is evident.
2. Materials and methods
87
2.1. Classic and 24-color cytogenetics
88
93
Cytogenetic preparations for hematopoietic and melanoma
tumor samples were prepared using established methods.
Spectral or 24-color karyotyping was performed using
residual cell pellets stored at −80 ◦ C as described previously [5]. Cytogenetic nomenclature followed ISCN (1995)
[6].
94
2.2. S-FISH assay
95
Residual cell pellets from cytogenetic samples stored
at −80 ◦ C and touch preparations of malignant melanoma
stored at −20 ◦ C were used for the S-FISH assay. Immediately prior to hybridization, cell pellets were washed in 3:1
methanol:glacial acetic acid (Carnoy’s fixative) solution and
dropped onto pre-cleaned, non-silanized slides. Slides were
pretreated in 2X SSC at 37 ◦ C for 30 min, dehydrated in an
ethanol series (70, 80 and 95% for 2 min each), denatured
in 70% formamide/2X SSC (pH 7.0) at 72 ◦ C for 2 min, and
then dehydrated again in an ethanol series. Touch preparations of metastatic melanoma were made from tumors
submitted to the SWOG Tumor Repository, Cincinnati, OH,
according to Southwest Oncology Group (SWOG) protocol
SWOG-9431. Touch preparations were made on silanized
slides, fixed in ice cold Carnoy’s fixative and air-dried.
92
96
97
98
99
100
101
102
103
104
105
106
107
108
109
Label
Targets of panel 1
5q31 (EGR1)a
5p15
7q22 (CUTL1)
7␣-Satellite
8␣-Satellite
RPCI-1 98O22
RPCI-11 35K22
H-RG 305102
pZ7.5
pZ8.4
Spectrum orange
Cy5.5
Texas red/Cy5.5
Texas red
Spectrum green
Targets of panel 2
13q14 (RB1)
13qtel
17p13.1 (TP53)
17q11.2 (HER2/neu)
20q11.2
20p13
RPCI-11 174i10
RPCI-11 190i5
RPCI-11 199f11
RPCI-11 62n23
RPCI-1 81g23
RPCI-11 48M7
Cy5.5
Spectrum orange
Texas red
Cy5.5/spectrum orange
Spectrum green
Cy5.5/spectrum green
a
Gene abbreviations: EGR1, early growth response 1; CUTL1, cut-like
1 or CDP/CCAAT displacement protein; RB1, retinoblastoma-1; TP53, tumor protein p53; HER2/neu, human EGF receptor/neuroblastoma-derived.
Samples were stored in a −20 ◦ C freezer until hybridization.
110
111
2.3. t-MDS/AML S-FISH probe panel
112
DNA probes that targeted non-random chromosomal
aberrations frequently reported for t-MDS/AML, namely,
−5/del(5q), −7/del(7q), +8/del(13q), del(17p) and del(20q)
were obtained. Eleven probes localized to six chromosomes
were used (Table 1). Probes for chromosomes 5, 13, 17 and
20 were obtained from Dr. Pieter J. de Jong, Children’s
Hospital Oakland Research Institute (CHORI). Probes for
the ␣-satellite regions of chromosome 8 (pZ8.4) and chromosome 7 (pZ7.5) were generous gifts from Dr. Mariano
Rocchi, University of Bari, Italy. The 7q22 DNA probe
(H-RG 305102) localized immediately telomeric to CUTL1
was a gift from Dr. Stephen W. Scherer, Hospital for Sick
Children, Toronto, Ont., Canada.
The malignant melanoma FISH probes were specifically
chosen based on previous studies implicating their potential
role in development or progression of malignant melanoma
[7–12]. In this study, FISH probes for six different target
genes/sites (LIBC, MART1, EGFR, and enumeration probes
for chromosomes 6, 7 and 9) were used to identify gene copy
number abnormalities in fresh tumor and touch preparations
of metastatic melanoma (Table 2). Probes targeting 6q22
(RPCI-11 28K19) and 9ptel (RPCI-11 147N16 including the
MART1 or melanoma antigen recognized by T cells 1 gene)
were obtained from Dr. Pieter J. de Jong at CHORI. Probes
for the ␣-satellite regions of chromosome 6 (pEDZ6), chromosome 7 (pZ7.5) and chromosome 9 (pMR9A) were gifts
from Dr. Mariano Rocchi, University of Bari, Italy. California Institute of Technology provided the probe targeting the
EGFR gene at 7p12.3 (2026N22).
Probe DNAs for the hematopoietic and melanoma samples
were isolated using the Qiafilter plasmid midi kit (Qiagen,
113
RR
91
CO
90
UN
89
Probe
EC
86
Table 1
Spectral FISH: t-MDS/AML DNA
OF
61
DP
RO
60
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
TE
2
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
3. Results
Table 2
Spectral FISH: melanoma DNA probe panel
6q22
6␣-Satellite
7p12.3 (EGFR)
7␣-Satellite
9ptel (MART1)
9␣-Satellite
3.1. Secondary AML
Probe
Label
RPCI-11 28K19
PEDZ6
2026N22
PZ7.5
RPCI-11 147N16
PMR9A
Cy5.5/spectrum green
Spectrum green
Texas red/Cy5.5
Texas red
Cy5.5
Spectrum orange
a
Gene abbreviations: LIBC, lost in inflammatory breast cancer; EGFR,
epidermal growth factor receptor; MART1, melanoma antigen recognized
by T cells 1.
169
2.4. Single and dual color FISH
170
Conventional FISH analyses were performed to confirm
the chromosomal location of each probe prior to initiation
of the analysis, to rule out cross hybridization, and to corroborate discrepant results. In addition to the probes mentioned earlier, P1 1069 (gift from Dr. Alexander Kamb,
Myriad Genetics Inc., Salt Lake City, UT) which contains
the p16I NK4a /MTS/CDKN2A gene, was used to test for 9p
interstitial deletions in melanoma. Slide pretreatment was
done as previously described for S-FISH assays. Hybridization followed standard procedure [14]. Biotin-labeled probes
were detected with FITC conjugated avidin (Roche Molecular Biochemicals, Indianapolis, IN) in 1X PBS, 1% blocking
reagent and 1% BSA for 5 min. Nuclei were counterstained
with DAPI. Lymphocytes from a normal male were used as
a negative control.
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
171
172
173
174
175
176
177
178
179
180
181
182
183
184
RR
147
CO
146
UN
145
EC
168
Valencia, CA) and labeled by nick translation using standard
technique.
Probe combinatorial labeling, spectral imaging and image
acquisition were performed as described [4]. Briefly, S-FISH
combinatorial labeling strategy used four fluorochromes:
spectrum orange, Texas red, spectrum green and Cy5.5. After the concentrations of each probe in the S-FISH panels were adjusted for equivalent fluorescence intensities,
the desired probe cocktails were combined and unincorporated nucleotides removed using the QIAquick Nucleotide
Removal Kit (Qiagen, Valencia, CA). Hybridization followed standard FISH procedures for locus-specific probes.
Biotin-labeled probes were detected with 2.5 ␮g/ml Cy5.5
conjugated avidin (Rockland, Gilbertsville, PA) in 1X PBS,
1% blocking reagent (Roche Molecular Biochemicals, Indianapolis, IN) and 1% BSA for 5 min. Nuclei were counterstained with 4 ,6 -diamindino-2-phenylindole (DAPI).
Spectral images were acquired and analyzed with the
SD200 SpectraCube system (Applied Spectral Imaging Ltd.,
Migdal Haemek, Israel) attached to a Zeiss Axioplan II microscope with a 150 W xenon UV light source. System calibration and scoring criteria followed described procedures
[4,13]. Validation of S-FISH was performed by classic cytogenetics and 24-color spectral karyotyping when metaphase
cells were available or by conventional FISH analyses.
144
A bone marrow sample collected from a 71-year-old male
with a diagnosis of acute myeloid leukemia evolving from
myelodysplastic syndrome (secondary AML) was chosen for
a comprehensive molecular cytogenetic work-up because
of its karyotypic complexity and the unclear relationship
between the observed aberrant hypodiploid and hyperdiploid clones. All mitotic cells collected for GTG-band
analysis were clonally abnormal. Clone 1 was characterized
by deletion of 5q, additional material of unknown origin
translocated to 11p, a ring chromosome 11, a suspected
paracentric inversion of 12p, deletion of 18q and losses of
chromosomes 17 and 20. The karyotypic designation of hypodiploid clone 1 was: 44,XY,del(5)(q22q3?1),add(11)(p15),
r(11)(p1?5q2?5),?inv(12)(p11.2p13.3),−17,del(18)(q2?2),−
20 [cp13] (Fig. 1A).
Clone 2 was hyperdiploid, with gains of chromosomes 2,
4, 6, 8, 9, 11, 13 and 21, losses of chromosomes 18 and 20,
an augmentation of 5q and smaller derivative chromosome
5s. One hypertetraploid cell containing a duplicate copy of
clone 2 aberrations was also collected. Losses and gains
among the hyperdiploid cells resulted in the use of a
composite karyotype with 51–56 chromosomes. The karyotypic designation of clone 2 was 51–56,XY,+2,+4,add(5)
(q?11.2)x2,+add(5)(q3?5),+6,+8,+8,+9,+11,+13,−18,−
20,+21 [cp6] (Fig. 1B).
Twenty-four-color karyotyping was performed to refine
analysis of the karyotypic aberrations observed in this case
and possibly to define a more robust relationship between the
two clones. In clone 1, the five aberrations were revised as
follows: del(5)(q22q3?1) to der(5)t(5;?17;19),add(11)(p15)
to der(11)t(5;11),?inv(12)(p11.2p13.3) to der(12)t(12;18), a
normal 16 to der(16)t(1;16) and del(18q) to der(18)t(16;18).
Because combinatorial fluorophore blending may occur at
the site of translocation, the questionable presence of chromosome 17 material as part of a three-way translocation
could not be established with the assay. In clone 2, the chromosome 5 aberrations were reassigned as der(5)t(5;17)x2,
der(5)t(5;19) with insertion of chromosome 5 material into a
derivative chromosome 10 and two apparently normal copies
of chromosome 17. Tetrasomy 8 was confirmed in clone 2
only. Monosomy 20 was observed in both clones.
Spectral FISH employed DNA FISH probe panels designed to screen for recurring cytogenetic aberrations in the
myelodysplastic syndromes and acute myeloid leukemias including −5/del(5q), −7/del(7q), +8/del(13q), abnormalities
of chromosome 17 including deletions and iso-chromosomes
and 20q deletions (Table 1). Because two clones were present, metaphase cells were collected to view the genes of
interest by location and copy number (Fig. 2A and B). In
clone 1, the first S-FISH panel identified disomy for chromosomes 7 and 8 with deletion of EGR1 (early growth
response 1) gene located at 5q31 in one chromosome 5.
DP
RO
(LIBC)a
TE
Targets
3
OF
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
CO
RR
EC
TE
DP
RO
OF
4
UN
Fig. 1. Cytogenetic analysis of sAML: (panel A) hypodiploid clone (clone 1). ISCN designation is 44,XY,del(5)(q22q3?1),add(11)(p15),r(11)(p1?5q2?5),?inv
(12)(p11.2p13.3),−17,del(18)(q2?2),−20 [cp13]. The 24-color karyotyping refined the karyotypic aberrations as follows: del(5)(q22q3?1) to der(5)t
(5;?17;19),add(11)(p15) to der(11)t(5;11),?inv(12)(p11.2p13.3) to der(12)t(12;18), a normal 16 to der(16)t(1;16) and del(18q) to der(18)t(16;18);
(panel B) hyperdiploid clone (clone 2). The karyotypic designation for clone 2 was 51–56,XY,+2,+4,add(5)(q?11.2)x2,+add(5)(q3?5),+6,+8,+8,+9,+11,+
13,−18,−20,+21 [cp6]. This cell contains only 53 chromosomes with random loss of chromosomes 11 and 13. The chromosome 5 aberrations were
reassigned after 24-color karyotyping as der(5)(5;17)x2,der(5)t(5;19) and ins(10;5). Tetrasomy 8 and two apparently normal copies of chromosome 17
were confirmed. Arrows point to clonal abnormalities. Monosomy 20 was observed in both clones.
5
RR
EC
TE
DP
RO
OF
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
240
241
242
243
244
The second panel revealed monosomy 20, loss of one TP53
(17p13) signal consistent with the loss of chromosome 17
identified by cytogenetics. However, two HER2/neu/17q12
signals were observed with the second signal localized to
the der(5), confirming a complex (three-way) unbalanced
5;17;19 translocation as suggested by 24-color analysis. In
UN
239
CO
Fig. 2. S-FISH in sAML: (panel A) in clone 1, S-FISH panel A identified disomy for chromosomes 7 and 8 with deletion of EGR1/5q31 in one
chromosome 5; (panel B) the second panel of probes revealed monosomy 20 with loss of one TP53/17p13 signal consistent with loss of one copy of
chromosome 17 identified by cytogenetics. Two HER2/neu/17q12 signals were observed with the second signal localized to the der(5), confirming a
complex (three-way) unbalanced 5;17;19 translocation as suggested by 24-color analysis (arrow); (panel C) in the hyperdiploid clone 2, S-FISH revealed
three 5p15 signals, one 5q31 signal, disomy 7 and tetrasomy 8. The der(5)t(5;19) did not appear to have chromosome 17 material but 17q12 material
was translocated to the two smaller derivative chromosome 5s (arrows); (panel D) S-FISH showed one TP53/17p13 signal with four HER2/neu/17q12
signals. The 17q12 signals were localized to the der(5)t(5;17)s, a normal chromosome 17 and an apparently del(17p), the latter not recognized as a
deletion by either classic or 24-color karyotyping.
clone 2, the der(5)t(5;19) did not appear to have 17 material,
although two smaller derivative chromosome 5s did have distal 17q12, der(5)t(5;17). S-FISH showed only one signal for
TP53/17p13 but four HER2/neu/17q12 signals with the two
remaining 17q12 signals, one localized to a normal chromosome 17 and the other on an unrecognized del(17p) (Fig. 2C
245
246
247
248
249
250
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
DP
RO
OF
6
UN
CO
RR
EC
TE
Fig. 3. Conventional FISH studies: (A and B) in the sAML case, dual color FISH using the 5p15 probe labeled in spectrum green and HER2/neu/17q12
probe labeled spectrum orange confirmed the der(5) rearrangements with chromosome 17 in clone 1 (A) and clone 2 (B). Arrows point to the der(5)s.
(C) Dual color FISH using the MART1/9ptel probe labeled in spectrum orange and the CDKN2A/p16/9p21 probe label in spectrum green confirms loss
of one copy of p16 gene in melanoma sample 165797.
Fig. 4. Malignant melanoma molecular cytogenetics: (A) 24-color karyotyping of SWOG-9431 malignant melanoma sample, 165797. The karyotypic
designation for this near-diploid tumor was 48,X,−X,+der(1)t(9;X;1)(p13;p11.?4;q10),t(5;16)(q31.1;q13),der(6) t(1;6)(q10;p10),+der(6)t(6;22)(p10;q10),+
7,del(9)(p22p24),der(9)t(X;9)(p11.?4;p13),der(13;15)(q10;q10),t(14;19)(q11.2;p13.3),+19,+20,−22 [20]. This cell has random loss of chromosomes 12, 19
and 20. Three clonal 9p aberrations were identified. Arrows point to clonal aberrations involving chromosomes 6, 7 and 9; (B–E) spectral FISH of a malignant
melanoma interphase cell from case 165797. (B) Spectral image of the interphase nucleus shown in panels C and D. (C) Classified image of same cell shown
in panels B and D. (D) DAPI image of the cell. (E) Spectral FISH profile shows concordance with the 24-color karyotyping observed in panel A. Note the
presence of three der(6) chromosomes with loss of 6q illustrated by loss of two copies of the LIBC gene, trisomy 7 and two MART1/ 9centromere signals.
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
254
3.2. Malignant melanoma
256
Cytogenetic and molecular cytogenetic studies were initiated on SWOG-9431 malignant melanoma samples. Fresh
tumor material was used for classic and 24-color cytogenetic
studies and touch preparations were prepared from frozen tumor material for S-FISH. For panel validation, a near diploid
tumor was chosen for S-FISH evaluation. The 25 mitotic
cells collected for GTG-band analysis and 24-color karyotyping from short-term tissue culture were clonally abnormal. An hyperdiploid stemline was characterized by gain of
a derivative chromosome 1 resulting from a complex translocation involving Xp and 9p, a translocation between 5q and
16q, a derivative chromosome 6 resulting from a whole-arm
translocation with 1q, gain of a derivative chromosome 6
resulting from a whole-arm translocation with 22q, deletion
of 9p, a derivative chromosome 9 resulting from a translocation with Xp, a Robertsonian t(13;15), a translocation
between proximal 14q and distal 19p, gains of additional
copies of chromosomes 7, 19 and 20 and losses of X and
22 (Fig. 4). The final karyotypic designation was 48,X,X,+der(1)t(9;X;1)(p13;p11.?4;q10),t(5;16)(q31.1;q13),der
(6)t(1;6)(q10;p10),+der(6)t(6;22)(p10;q10),+7,del(9)(p22p
24),der(9)t(X;9) (p11.?4;p13),der(13;15) (q10;q10),t(14;19)
(q11.2;p13.3),+19,+20,−22 [20].
S-FISH confirmed the presence of three derivative 6 chromosomes with loss of the LIBC/6q22 chromosomal region in
two copies, trisomy 7, and two copies (disomy) for chromosome 9 and the 9p telomeric region containing the MART1
gene. Because three 9p clonal aberrations were apparent by
cytogenetics, dual color FISH tested for the possibility of
p16INK4a deletions. Loss of one p16/9p21 signal with two
copies of MART1/9ptel in this melanoma case, indicated
translocation of MART1 to chromosome 1 and an interstitial
9p deletion (Fig. 3C).
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
RR
258
CO
257
EC
255
4. Discussion
290
Molecular cytogenetics and FISH-based assays can contribute to improve cancer risk assessment. Previously, we
reported the value of S-FISH for the assessment of minimal
residual disease (MRD) by simultaneous detection of multiple numeric aberrations (aneuploidy) in a single hybridization [4]. S-FISH probe panels have been redesigned to detect
disease-specific chromosomal targets; the simultaneous use
of selected DNA probes provides internal confirmation of
suspected losses or gains, increases the information gained
from each assay, and most importantly, increases the clinical
utility of the assay.
292
293
294
295
296
297
298
299
300
UN
289
291
Significant levels of karyotypically aberrant cells have
been reported by conventional FISH in pre-transplant
samples taken from patients who developed t-MDS/AML
post-transplant for non-Hodgkin’s lymphoma [15,16]. One
of our goals was to develop a DNA probe panel for the common t-MDS/AML aberrations. The intended application is
to screen apheresis samples prior to autologous hematopoietic stem cell transplantation, particularly, in cases where
the transplant candidates have received high doses of prior
cytotoxic therapy. In this study, S-FISH applying DNA
probes targeting 11 chromosome sites on six chromosomes
was used to examine a karyotypically complex sAML case.
It enabled definition of the poorly understood relationship
between two vastly different clones and clarified the nature
of aberrations involving chromosomes that are commonly
reported in therapy-related MDS/AML. Although 24-color
karyotyping defined two chromosome 5 aberrations in clone
1 as der(5)t(5;?17;19) and der(11)t(5;11), the questionable
presence of chromosome 17 material as part of a three-way
translocation in the der(5)t(5;?17;19) could not be established by this method. The combinatorial labeling profiles
of these chromosomes varied by only one fluorochrome
and blending of fluorescence emission spectra characteristic
of each individual chromosome occurs with chromosomal
rearrangements. As a result, the faint hint of an additional
hybridization band at the translocation junction required
confirmation using DNA region-specific probes. In this case,
S-FISH and dual color FISH confirmed the presence of
chromosome 17 material, and in addition, S-FISH identified
the translocated chromosome 17 segment as 17q12 containing the HER2/neu gene, as part of a complex (three-way)
unbalanced t(5;17;19)(q22;q12;?).
The relationship between the hypodiploid and hyperdiploid clones in this sAML case was obscured by differing
clone-specific aberrations. We also note that massive hyperdiploidy is an unusual finding in sAML [17,18]. With
24-color karyotyping, we identified four aberrations in clone
2 with chromosome 5 material, der(5)t(5;19), two copies
of der(5)t(5;17) and an insertion of chromosome 5 material
into 10q. In comparison there were only two chromosome 5
aberrations in clone 1, der(5)t(5;17;19) and der(11)t(5;11).
In clone 2, S-FISH revealed one signal for 17p13 indicating
a small submicroscopic deletion in one apparently normal
chromosome 17, resulting in loss of a TP53 gene, despite
the presence of four HER2/neu/17q12 signals, corroborating the 24-color karyotype. Comparison of the two clones
revealed loss of 5q chromosomal material, loss of TP53,
translocation of chromosome 17q12 material to 5q and
monosomy 20 as common aberrations between them. Of
interest, at follow-up 1 month later, the hyperdiploid clone
was no longer evident and the hypodiploid clone showed
additional evidence of clonal evolution. These observations reinforce the impression that vast genetic instability
may be associated with an evolving acute leukemia arising
from myelodysplasia in association with loss of TP53. Importantly for future studies, probe selection for detection
OF
253
and D). Dual color FISH using the 5p15/17q12 probe combination confirmed der(5) rearrangements with chromosome
17 for both clones (Fig. 3A and B). The chromosome 5 material inserted into 10q was not composed of EGR1 or 5p15.
DP
RO
252
TE
251
7
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
Acknowledgements
422
The authors wish to thank Dr. Sandra Wolman for her
critical review of this manuscript. This work was supported
in part by NIH Grants CA30206, CA32102 and a private
donation from the Bernard Ruttenberg family.
423
References
427
[1] Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator
potentially involved in genesis of many tumor types. Science 1994;
264:436–40.
[2] Cachia AR, Indsto JO, McLaren KM, et al. CDKN2A mutation and
deletion status in thin and thick primary melanoma. Clin Cancer Res
2000;6:3511–5.
[3] Sawyers CL. Rational therapeutic intervention in cancer: kinases as
drug targets. Curr Opin Genet Dev 2002;12:111–5.
[4] Slovak ML, Tcheurekdjian L, Zhang FF, Murata-Collins JL. Simultaneous detection of multiple genetic aberrations in single cells by
spectral fluorescence in situ hybridization. Cancer Res 2001;61:831–
6.
[5] Zhang FF, Murata-Collins JL, Gaytan P, et al. 24-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal
acute myeloid leukemia. Genes Chromo Cancer 2000;28:318–
28.
[6] Mitelman F, editor. ISCN (1995): an international system for human
cytogenetic nomenclature. Basel: S. Karger, 1995.
[7] Slominski A, Wortsman J, Carlson AJ, et al. Malignant melanoma:
an update. Arch Pathol Lab Med 2001;125:1295–306.
[8] Bittner M, Meltzer P, Chen Y, et al. Molecular classification of
cutaneous malignant melanoma by gene expression profiling. Nature
2000;406:536–40.
[9] Miele ME, Jewett MD, Goldberg SF, et al. A human melanoma
metastasis-suppressor locus maps to 6q16.3–q23. Int J Cancer 2000;
86:524–8.
[10] Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of
metastasis reveals an essential role for RhoC. Nature 2000;406:532–
5.
[11] Wang ZH, Ding MX, Jin ML, et al. Association of EGFR gene
fragments with nuclear matrix proteins in high and low metastatic
melanoma cell lines. Anticancer Res 1999;19:4349–52.
[12] van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity
insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511–
9.
[13] Fung J, Hyun W, Dandekar P, et al. Spectral imaging in preconception/preimplantation genetic diagnosis of aneuploidy: multicolor,
multi-chromosome screening of single cells. J Assist Reprod Genet
1998;15:323–30.
428
429
430
OF
362
DP
RO
361
413
EC
360
In summary, advances in molecular oncology and genomics will increasingly impact the clinical arena. New gene
targets will be developed for use as diagnostic markers, prognostic risk factors, and potential sites for directed therapeutic intervention. Our preliminary studies with S-FISH suggest that this assay may contribute substantially to determination of tumor subtype, detection of residual disease, disease progression and, perhaps in the near future, response
to treatment.
RR
359
of chromosome 5, 17 and 20 aberrations in t-MDS/AML
appears to be suitable for further analyses.
The SWOG Melanoma Biologics and Cytogenetics Committees recently initiated pilot cytogenetic and S-FISH studies on a subgroup of SWOG-9431 malignant melanoma
tumors. As illustrated in our case, melanoma karyotypes
are typically highly aneuploid with multiple numerical and
structural aberrations, often involving chromosomes 1, 6, 7
and 9. Structural aberrations of chromosome 1 are found in
∼60% and rearrangements of chromosome 6 are found in
nearly 80% of abnormal cases, frequently resulting in 6q loss
[19]. Abnormalities of chromosome 9 can be numerical or
structural, with deletion of 9p21 sequences particularly frequent. The 9p21 contains the p16INK4a locus, a site known
to be critical for normal progression through the cell cycle
[2]. Trisomy 7 is another recurrent finding in melanoma; implying that additional copies of genes on this chromosome
including EGFR may play a role in melanoma development
or tumor progression [20]. The S-FISH DNA probe panel
for melanoma was selected based on a literature search of
genes involved in melanoma development and progression.
In preliminary analyses, the S-FISH assay proved reliable
in the detection of loss of 6q22 and trisomy 7, with retention of two signals for MART1/9ptel and chromosome 9
centromere. However, the complexity of the genetic aberrations found in metastatic melanoma underscores the need to
define reliable genetic markers to improve prognostication
and identify new treatments for primary and advanced stage
melanoma. We plan to refine a panel of DNA FISH probes
that identify alterations in genes in malignant melanoma
cells, based on their role in growth regulation, apoptosis, invasion/metastases, angiogenesis, and DNA repair. We expect
that specific alterations in gene copy or the pattern of alterations observed in metastatic disease will serve as prognostic
markers for progression of primary stage melanoma. Additionally, some genes (i.e. EGFR, C-KIT) may be identified
as molecular targets to pursue with novel treatments, such
as specific tyrosine kinase inhibitors, monoclonal antibodies
or ligands capable of binding to cell surface receptors for
growth factors in either advanced or early stage of disease.
Despite the improved genetic diagnostic accuracy with
S-FISH, we are aware of the need to overcome some technical challenges. The three dimensional aspects of interphase
nuclei are problematic for FISH-based assays. In S-FISH
this difficulty is amplified because the multiplicity of signals
prohibits an accurate quantitative evaluation of overlapping
signals, as well as the capturing of signals at different focal
planes. These obstacles, and the labor intensity of combinatorial labeling and screening, indicate the needs for improved probe labeling, Z-stacking software, and automated
spot counting. The incorporation of Z-stacking software and
motorized microscopy should allow for automation in the
near future. It would permit evaluation of fluorescence intensity of probe signals measured through different planes in
the sample to produce a sharply detailed three-dimensional
composite image of a single cell in two dimensions.
CO
358
UN
357
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
TE
8
414
415
416
417
418
419
420
421
424
425
426
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
M.L. Slovak et al. / Cancer Detection and Prevention 32 (2002) 1–9
DP
RO
OF
[17] Johanssen B, Mertens F, Heim S, et al. Cytogenetics of secondary
myelodysplasia (sMDS) and acute non-lymphocytic leukemia
(sANLL). Eur J Haematol 1991;47:17–27.
[18] Padua RA, McGlynn A, McGlynn H, et al. Molecular, cytogenetic
and genetic abnormalities in MDS and secondary AML. Cancer Treat
Res 2001;108:111–57.
[19] Nelson MA, Radmacher MD, Simon R, et al. Chromosome abnormalities in malignant melanoma: clinical significance of non-random
chromosome abnormalities in 206 cases. Cancer Genet Cytogenet
2000;122:101–9.
[20] Udart M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A
marker for metastatic melanoma? Expression of the epidermal growth
factor receptor gene and chromosome 7 aneusomy in nevi, primary
malignant melanomas and metastases. Neoplasia 2001;3:245–54.
CO
RR
EC
TE
[14] Zhang FF, Arber DA, Wilson TG, et al. Toward the validation of
aneusomy detection by fluorescence in situ hybridization (FISH) in
bladder cancer: comparative analysis with cytology, cytogenetics,
and clinical features predicts recurrence and defines clinical testing
limitations. Clin Cancer Res 1997;3:2317–28.
[15] Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal
pre-transplant clones in progenitor cells of patients who developed
myelodysplasia after autologous transplantation. Blood 1999;94:
1814–9.
[16] Lillington DM, Micallef INM, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing
therapy-related myelodysplasia and secondary acute myelogenous
leukemia after treatment for non-Hodgkin’s lymphoma. J Clin Oncol
2001;19:2472–81.
UN
469
470
471
472
473
474
475
476
477
478
479
480
481
482
9
483
484
485
486
487
488
489
490
491
492
493
494
495
496